nach oben

Journal of Neural Transmission

Erschienen in:

07.03.2018 | Neurology and Preclinical Neurological Studies - Review Article

Kinetics, mechanism, and inhibition of monoamine oxidase

verfasst von: Rona R. Ramsay, Alen Albreht

Erschienen in: Journal of Neural Transmission | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs. While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design. In neurodegenerative diseases, MAO inhibitors can help to maintain neurotransmitter levels, making it a common feature in novel multi-target combinations designed to combat Alzheimer’s disease, albeit not yet proven clinically. Vital information for inhibitor design comes from an understanding of the structure, mechanism, and kinetics of the catalyst. This review will summarize the kinetic behaviour of MAO A and B and the kinetic evaluation of reversible inhibitors that transiently decrease catalysis. Kinetic parameters and crystal structures have enabled computational approaches to ligand discovery and validation of hits by docking. Kinetics and a wide variety of substrates and inhibitors along with theoretical modelling have also contributed to proposed schemes for the still debated chemical mechanism of amine oxidation. However, most of the marketed MAO drugs are long-lasting irreversible inactivators. The mechanism of irreversible inhibition by hydrazine, cyclopropylamine, and propargylamine drugs will be discussed. The article finishes with some examples of the propargylamine moiety in multi-target ligand design to combat neurodegeneration.

Abad E, Zenn RK, Kaestner J (2013) Reaction mechanism of monoamine oxidase from QM/MM calculations. J Phys Chem B 117(46):14238–14246. https://doi.org/10.1021/jp4061522 CrossRefPubMed

Akyuz MA, Erdem SS (2013) Computational modeling of the direct hydride transfer mechanism for the MAO catalyzed oxidation of phenethylamine and benzylamine: ONIOM (QM/QM) calculations. J Neural Transm 120:937–945. https://doi.org/10.1007/s00702-013-1027-8 CrossRefPubMed

Akyuz MA, Erdem SS, Edmondson DE (2007) The aromatic cage in the active site of monoamine oxidase B: effect on the structural and electronic properties of bound benzylamine and p-nitrobenzylamine. J Neural Transm 114(6):693–698PubMed

Apostolov R, Yonezawa Y, Standley DM, Kikugawa G, Takano Y, Nakamura H (2009) Membrane attachment facilitates ligand access to the active site in monoamine oxidase A. Biochemistry 48(25):5864–5873PubMed

Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human-liver monoamine oxidase-A and oxidase-B—molecular basis of differences in enzymatic properties. PNAS USA 85(13):4934–4938PubMedPubMedCentral

Baker GB, Wong JT, Yeung JM, Coutts RT (1991) Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 21(3):207–211PubMed

Basile L, Pappalardo M, Guccione S, Milardi D, Ramsay RR (2014) Computational comparison of imidazoline association with the 12 binding site in human monoamine oxidases. J Chem Inf Model 54(4):1200–1207PubMed

Bautista-Aguilera OM et al (2014a) Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem 75:82–95. https://doi.org/10.1016/j.ejmech.2013.12.028 CrossRefPubMed

Bautista-Aguilera OM et al (2014b) N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4yl)propoxy)-1H- indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J Med Chem 57(24):10455–10463. https://doi.org/10.1021/jm501501a CrossRefPubMed

Bautista-Aguilera O et al (2017) Multitarget-directed ligands combining cholinesterase and monoamine oxidase Inhibition with H3R antagonism for neurodegenerative diseases. Angew Chem 56:12765–12769. https://doi.org/10.1002/anie.201706072 CrossRef

Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9(1):22–26PubMed

Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A (2003) Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 100(17):9750–9755PubMedPubMedCentral

Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47(7):1767–1774PubMed

Binda C, Hubalek F, Li M, Castagnoli N, Edmondson DE, Mattevi A (2006) Structure of the human mitochondrial monoamine oxidase B—new chemical implications for neuroprotectant drug design. Neurology 67(7):S5–S7PubMed

Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50(23):5848–5852PubMed

Binda C, Wang J, Li M, Hubalek F, Mattevi A, Edmondson DE (2008) Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry 47(20):5616–5625PubMed

Binda C et al (2010) Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc 132(19):6827–6833PubMed

Binda C, Mattevi A, Edmondson DE (2011) Structural properties of human monoamine oxidases A AND B. In: Youdim MBH, Riederer P (eds) Monoamine oxidases and their inhibitors. Int Rev Neurobiol 100:1–11. https://doi.org/10.1016/b978-0-12-386467-3.00001-7

Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE (2012) Molecular insights into human monoamine oxidase B inhibition by the glitazone antidiabetes drugs. Med Chem Lett 3(1):39–42

Bocchinfuso R, Robinson JB (1999) The stereoselectivity of inhibition of rat liver mitochondrial MAO-A and MAO-B by the enantiomers of 2-phenylpropylamine and their derivatives. Eur J Med Chem 34(4):293–300. https://doi.org/10.1016/S0223-5234(99)80080-4 CrossRef

Bolea I, Juarez-Jimenez J, de los Rios C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and N-(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl-N-methylprop-2-yn-1-ami ne hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease. J Med Chem 54(24):8251–8270. https://doi.org/10.1021/jm200853t CrossRefPubMed

Bonnet U (2002) Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug REV 8(3):283–308PubMedPubMedCentral

Borroni E et al (2017) Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. J Pharmacol Exp Ther 362(3):413–423. https://doi.org/10.1124/jpet.117.241653 CrossRefPubMed

Borstnar R, Repic M, Krzan M, Mavri J, Vianello R (2011) Irreversible inhibition of monoamine oxidase B by the antiparkinsonian medicines rasagiline and selegiline: a computational study. Eur J Org Chem 32:6419–6433. https://doi.org/10.1002/ejoc.201100873 CrossRef

Bortolato M, Shih JC (2011) Behavioral outcomes of monoamine oxidase deficiency: Preclinical and clinical evidence. In: Youdim MBH, Riederer P (eds) Monoamine oxidases and their inhibitors. Int Rev Neurobiol 100:13–42. https://doi.org/10.1016/b978-0-12-386467-3.00002-9

Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG (2006) Safinamide—from molecular targets to a new anti-Parkinson drug. Neurology 67(7):S18–S23PubMed

Cakir K, Erdem SS, Atalay VE (2016) ONIOM calculations on serotonin degradation by monoamine oxidase B: insight into the oxidation mechanism and covalent reversible inhibition. Org Biomol Chem 14(39):9239–9252. https://doi.org/10.1039/c6ob01175f CrossRefPubMed

Carradori S, Silvestri R (2015) New frontiers in selective human MAO-B inhibitors. J Med Chem 58(17):6717–6732. https://doi.org/10.1021/jm501690r CrossRefPubMed

Cesura AM, Pletscher A (1992) The new generation of monoamine oxidase inhibitors. Prog Drug Res (Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques) 38:171–297

Chajkowski-Scarry S, Rimoldi JM (2014) Monoamine oxidase A and B substrates: probing the pathway for drug development. Future Med Chem 6(6):697–717. https://doi.org/10.4155/fmc.14.23 CrossRefPubMed

Chiuccariello L et al (2016) Monoamine oxidase-A occupancy by moclobemide and phenelzine: implications for the development of monoamine oxidase inhibitors. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyv078 CrossRef

Copeland RA, Lombardo D, Giannaras J, Decicco CP (1995) Estimating K-i values for tight-binding inhibitors from dose–response plots. Bioorg Med Chem Lett 5(17):1947–1952. https://doi.org/10.1016/0960-894x(95)00330-v CrossRef

Cruz F, Edmondson DE (2007) Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. J Neural Transm 114(6):699–702PubMed

Culhane JC, Wang D, Yen PM, Cole PA (2010) Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 132(9):3164–3176. https://doi.org/10.1021/ja909996p CrossRefPubMedPubMedCentral

Da Prada M et al (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 29:279–292

De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. PNAS USA 102(36):12684–12689PubMedPubMedCentral

Delport A, Harvey BH, Petzer A, Petzer JP (2017) The monoamine oxidase inhibition properties of selected structural analogues of methylene blue. Toxicol Appl Pharmacol 325:1–8. https://doi.org/10.1016/j.taap.2017.03.026 CrossRefPubMed

Desideri N, Proietti Monaco L, Fioravanti R, Biava M, Yanez M, Alcaro S, Ortuso F (2016) (E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. Eur J Med Chem 117:292–300. https://doi.org/10.1016/j.ejmech.2016.03.081 CrossRefPubMed

Dorris RL (1982) A simple method for screening monoamine oxidase (MAO) inhibitory drugs for type preference. J Pharmacol Methods 7(2):133–137PubMed

Dunn RV, Marshall KR, Munro AW, Scrutton NS (2008) The pH dependence of kinetic isotope effects in monoamine oxidase A indicates stabilization of the neutral amine in the enzyme-substrate complex. FEBS J 275(15):3850–3858. https://doi.org/10.1111/j.1742-4658.2008.06532.x CrossRefPubMed

Dunn RV, Munro AW, Turner NJ, Rigby SEJ, Scrutton NS (2010) Tyrosyl radical formation and propagation in flavin dependent monoamine oxidases. ChemBioChem 11(9):1228–1231PubMed

Edmondson DE, Newton-Vinson P (2001) The covalent FAD of monoamine oxidase: structural and functional role and mechanism of the flavinylation reaction. Antioxid Redox Signal 3(5):789–806PubMed

Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F (2004) Structure and mechanism of monoamine oxidase. Curr Med Chem 11(15):1983–1993PubMed

Edmondson DE, Binda C, Mattevi A (2007) Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys 464(2):269–276PubMedPubMedCentral

Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A (2009) Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 48(20):4220–4230PubMed

Efange SM, Boudreau RJ (1991) Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Comput Aided Mol Des 5(5):405–417PubMed

Efange SMN, Michelson RH, Tan AK, Krueger MJ, Singer TP (1993) Molecular-size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs of monoamine oxidase-A and oxidase-B. J Med Chem 36(9):1278–1283PubMed

Esteban G, Allan J, Samadi A, Mattevi A, Unzeta M, Marco-Contelles J, Binda C, Ramsay RR (2014) Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer’s disease. Biochem Biophys Acta 1844(6):1104–1110PubMed

Finberg J, Rabey J (2016) Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol 7:340. https://doi.org/10.3389/fphar.2016.00340 CrossRefPubMedPubMedCentral

Fisar Z (2016) Drugs related to monoamine oxidase activity. Prog Neuro Psychopharmacol Biol Psychiatry 69:112–124. https://doi.org/10.1016/j.pnpbp.2016.02.012 CrossRef

Fitzpatrick PF (2010) Oxidation of amines by flavoproteins. Arch Biochem Biophys 493(1):13–25PubMed

Fitzpatrick PF, Villafranca JJ (1986) The mechanism of inactivation of dopamine beta-hydroxylase by hydrazines. J Biol Chem 261(10):4510–4518PubMed

Fowler CJ, Oreland L (1980) The nature of the substrate-selective interaction between rat liver mitochondrial monoamine-oxidase and oxygen. Biochem Pharmacol 29(16):2225–2233PubMed

Fowler CJ, Mantle TJ, Tipton KF (1982) The nature of the inhibition of rat-liver monoamine-oxidase type-A and type-B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol 31(22):3555–3561PubMed

Fowler JS, Logan J, Shumay E, Alia-Klein N, Wang G-J, Volkow ND (2015) Monoamine oxidase: radiotracer chemistry and human studies. J Label Compd Radiopharm 58(3):51–64. https://doi.org/10.1002/jlcr.3247 CrossRef

Fraaije MW, Mattevi A (2000) Flavoenzymes: diverse catalysts with recurrent features. Trends Biochem Sci 25(3):126–132PubMed

Fuentes JA, Oleshansky MA, Neff NH (1976) Comparison of apparent antidepressant activity of (−) and (+) tranylcypromine in an animal-model. Biochem Pharmacol 25(7):801–804. https://doi.org/10.1016/0006-2952(76)90150-7 CrossRefPubMed

Garcia-Miralles M, Ooi J, Ferrari Bardile C, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA (2016) Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp Neurol 278:4–10. https://doi.org/10.1016/j.expneurol.2016.01.019 CrossRefPubMed

Gartner B, Hemmerich P, Zeller EA (1976) Structure of flavin adducts with acetylenic substrates—chemistry of monoamine-oxidase and lactate oxidase Inhibition. Eur J Biochem 63(1):211–221PubMed

Geha RM, Chen K, Shih JC (2000) Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. J Neurochem 75(3):1304–1309PubMed

Geha RM, Rebrin I, Chen K, Shih JC (2001) Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J Biol Chem 276(13):9877–9882PubMed

Griebel G, Curet O, Perrault G, Sanger DJ (1998) Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacol 37(7):927–935. https://doi.org/10.1016/S0028-3908(98)00077-X CrossRef

Guzior N, Wieckowska A, Panek D, Malawska B (2015) Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr Med Chem 22(3):373–404PubMedPubMedCentral

Hanzlik RP, Tullman RH (1982) Suicidal Inactivation of cytochrome-P-450 by cyclopropylamines—evidence for cation-radical intermediates. J Am Chem Soc 104(7):2048–2050

Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol (Oxford, England) 27(6):479–496. https://doi.org/10.1177/0269881113482532 CrossRef

Holt A, Palcic MM (2006) A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat Protoc 1:2498–2505PubMed

Hroch L et al (2017) Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment. Bioorg Med Chem 25(3):1143–1152. https://doi.org/10.1016/j.bmc.2016.12.029 CrossRefPubMed

Hruschka S, Rosen TC, Yoshida S, Kirk KL, Froehlich R, Wibbeling B, Haufe G (2008) Fluorinated phenylcyclopropylamines. Part 5: effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines. Bioorg Med Chem 16(15):7148–7166PubMedPubMedCentral

Huang P-KC, Kosower EM (1967) Properties of phenyldiimide. J Am Chem Soc 89(15):3910–3911. https://doi.org/10.1021/ja00991a047 CrossRef

Hubalek F, Binda C, Li M, Herzig Y, Sterling J, Youdim MB, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem 47(7):1760–1766. https://doi.org/10.1021/jm0310885 CrossRefPubMed

Hubalek F, Binda C, Khalil A, Li M, Mattevi A, Castagnoli N, Edmondson DE (2005) Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 280(16):15761–15766PubMed

Husain M, Edmondson DE, Singer TP (1982) Kinetic-studies on the catalytic mechanism of liver monoamine oxidase. Biochemistry 21(3):595–600PubMed

Hutson PH, Tarazi FI, Madhoo M, Slawecki C, Patkar AA (2014) Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders. Pharmacol Ther 143(3):253–264. https://doi.org/10.1016/j.pharmthera.2014.03.005 CrossRefPubMed

Hynson RMG, Wouters J, Ramsay RR (2003) Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochem Pharmacol 65(11):1867–1874PubMed

Hynson R, Kelly S, Price N, Ramsay R (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochem Biophys Acta 1672(1):60–66. https://doi.org/10.1016/j.bbagen.2004.02.011 CrossRefPubMed

Jones T, Balsa D, Unzeta M, Ramsay R (2007) Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better. J Neural Transm 114(6):707–712. https://doi.org/10.1007/s00702-007-0675-y CrossRefPubMed

Jonsson T, Edmondson DE, Klinman JP (1994) Hydrogen tunneling in the flavoenzyme monoamine-oxidase-B. Biochemistry 33(49):14871–14878PubMed

Joubert J, Foka GB, Repsold BP, Oliver DW, Kapp E, Malan SF (2017) Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem 125:853–864. https://doi.org/10.1016/j.ejmech.2016.09.041 CrossRefPubMed

Juarez-Jimenez J, Mendes E, Galdeano C, Martins C, Silva D, Marco-Contelles J, Carreiras M, Luque F, Ramsay R (2014) Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochem Biophys Acta 1844(2):389–397. https://doi.org/10.1016/j.bbapap.2013.11.003 CrossRefPubMed

Juárez-Jiménez J, Mendes E, Galdeano C, Martins C, Silva DB, Marco-Contelles J, Carreiras MdC, Luque FJ, Ramsay RR (2014) Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochim Biophys Acta (Proteins Proteom) 1844:389–397. https://doi.org/10.1016/j.bbapap.2014.03.006 CrossRef

Kacar B, Edmondson D (2006) Studies on the role of lysine-296 in human mitochondrial monoamine oxidase B catalysis. FASEB J 20(4):A478

Kalgutkar AS, Castagnoli N, Testa B (1995) Selective inhibitors of monoamine-oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med Res Rev 15(4):325–388PubMed

Kalgutkar AS, Dalvie DK, Castagnoli N, Taylor TJ (2001) Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: sAR studies on MAO substrates and inhibitors. Chem Res Toxicol 14(9):1139–1162PubMed

Kalir A, Sabbagh A, Youdim MB (1981) Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73(1):55–64PubMedPubMedCentral

Kay CWM, El Mkami H, Molla G, Pollegioni L, Ramsay RR (2007) Characterization of the covalently bound anionic flavin radical in monoamine oxidase a by electron paramagnetic resonance. J Am Chem Soc 129(51):16091–16097PubMed

Kearney EB, Salach JI, Walker WH, Seng RL, Kenney W, Zeszotek E, Singer TP (1971) Covalently-bound flavin of hepatic monoamine oxidase.1. Isolation and sequence of a flavin peptide and evidence for binding at 8 alpha-position. Eur J Biochem 24(2):321–327PubMed

Khan MNA, Suzuki T, Miyata N (2013) An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. Med Res Rev 33(4):873–910PubMed

Kim J-M, Hoegy SE, Mariano PS (1995) Flavin chemical models for monoamine oxidase inactivation by cyclopropylamines, alpha-silylamines, and hydrazines. J Am Chem Soc 117(1):100–105. https://doi.org/10.1021/ja00106a012 CrossRef

Kim H, Sablin S, Ramsay R (1997) Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337(1):137–142. https://doi.org/10.1006/abbi.1996.9771 CrossRefPubMed

Kim D, Baik SH, Kang S, Cho SW, Bae J, Cha MY, Sailor MJ, Mook-Jung I, Ahn KH (2016) Close correlation of monoamine oxidase activity with progress of alzheimer’s disease in mice, observed by in vivo two-photon imaging. ACS Cent Sci 2(12):967–975. https://doi.org/10.1021/acscentsci.6b00309 CrossRefPubMedPubMedCentral

Kitz R, Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245–3249PubMed

Kosower EM (1971) Monosubstituted diazenes (diimides). Surprising intermediates. Acc Chem Res 4(6):193–198. https://doi.org/10.1021/ar50042a001 CrossRef

Kupershmidt L, Amit T, Bar-Am O, Youdim MBH, Weinreb O (2012) The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer’s disease. Antioxid Redox Signal 17(6):860–877. https://doi.org/10.1089/ars.2011.4279 CrossRefPubMed

Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacol 10(4):231–238. https://doi.org/10.1038/npp.1994.26 CrossRef

Li M, Binda C, Mattevi A, Edmondson DE (2006) Functional role of the “aromatic cage” in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. Biochemistry 45(15):4775–4784PubMed

Li XF, Yu JJ, Zhu Q, Qian LH, Li L, Zheng YG, Yao SQ (2014a) Visualization of monoamine oxidases in living cells using “Turn-ON” fluorescence resonance energy transfer probes. Analyst 139(23):6092–6095. https://doi.org/10.1039/c4an01195c CrossRefPubMed

Li XF, Zhang HT, Xie YS, Hu Y, Sun HY, Zhu Q (2014b) Fluorescent probes for detecting monoamine oxidase activity and cell imaging. Org Biomol Chem 12(13):2033–2036. https://doi.org/10.1039/c3ob42326c CrossRefPubMed

Li LL, Li K, Liu YH, Xu HR, Yu XQ (2016) Red emission fluorescent probes for visualization of monoamine oxidase in living cells. Sci Rep. https://doi.org/10.1038/srep31217 CrossRefPubMedPubMedCentral

Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M (1996) Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 52(2):187–195PubMed

Ma JC, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T (2004) Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J Mol Biol 338(1):103–114PubMed

MacMillar S, Edmondson DE, Matsson O (2011) Nitrogen kinetic isotope effects for the monoamine oxidase B-catalyzed oxidation of benzylamine and (1,1-(2)H(2))benzylamine: nitrogen rehybridization and CH bond cleavage are not concerted. J Am Chem Soc 133(32):12319–12321PubMed

Magyar K, Palfi M, Jenei V, Szoko E (2006) Deprenyl: from chemical synthesis to neuroprotection. J Neural Transm Suppl 71:143–156

Malcomson T, Yelekci K, Borrello MT, Ganesan A, Semina E, De Kimpe N, Mangelinckx S, Ramsay RR (2015) cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. FEBS J 282(16):3190–3198. https://doi.org/10.1111/febs.13260 CrossRefPubMed

Mangiatordi GF et al (2017) A rational approach to elucidate human monoamine oxidase molecular selectivity. Eur J Pharm Sci 101:90–99. https://doi.org/10.1016/j.ejps.2017.02.008 CrossRefPubMed

Mantle TJ, Tipton KF, Garrett NJ (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25(18):2073–2077PubMed

Marco-Contelles J, Unzeta M, Bolea I, Esteban G, Ramsay RR, Romero A, Martnez-Murillo R, Carreiras MC, Ismaili L (2016) ASS234, as a new multi-target directed propargylamine for Alzheimer’s disease therapy. Front Neurosci. https://doi.org/10.3389/fnins.2016.00294 CrossRefPubMedPubMedCentral

Matsumoto T, Suzuki O, Furuta T, Asai M, Kurokawa Y, Nimura Y, Katsumata Y, Takahashi I (1985) A sensitive fluorometric assay for serum monoamine-oxidase with kynuramine as substrate. Clin Biochem 18(2):126–129PubMed

Maycock AL, Abeles RH, Salach JI, Singer TP (1976a) The action of acetylenic inhibitors on mitochondrial monoamine oxidase: structure of the flavin site in the inhibited enzyme. In: Bernheim MLC (ed) Monoamine oxidase and its inhibition, Ciba foundation symposium, vol 439. Wiley, pp 33–47. https://doi.org/10.1002/9780470720219.ch3

Maycock AL, Abeles RH, Salach JI, Singer TP (1976b) Structure of covalent adduct formed by interaction of 3-dimethylamino-1-propyne and flavin of mitochondrial amine oxidase. Biochemistry 15(1):114–125PubMed

Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R (1993) 5- 4-(Benzyloxy)phenyl -1,3,4-oxadiazol-2(3h)-one derivatives and related analogs—new reversible, highly potent, and selective monoamine-oxidase type-B inhibitors. J Med Chem 36(9):1157–1167PubMed

McCoubrey A (1957) Inhibition of monoamine oxidase by 1-phenylethylamines. Biochem Pharmacol 2(4):264–269. https://doi.org/10.1016/0006-2952(59)90039-5 CrossRef

McDonald AG, Tipton KF (2012) Enzymes: irreversible inhibition. In: eLS. John Wiley & Sons Ltd, Chichester. https://doi.org/10.1002/9780470015902.a0000601.pub2

McDonald GR, Olivieri A, Ramsay RR, Holt A (2010) On the formation and nature of the imidazoline I(2) binding site on human monoamine oxidase-B. Pharmacol Res 62(6):475–488PubMed

Medvedev AE et al (1999) inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR analysis. Neurobiology 7(2):151–158PubMed

Mefford IN, Roth KA, Jurik SM, Collman V, McIntire S, Tolbert L, Barchas JD (1985) Epinephrine accumulation in rat brain after chronic administration of pargyline and LY 51641—comparison with other brain amines. Brain Res 339(2):342–345PubMed

Meiring L, Petzer JP, Petzer A (2013) Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives. Bioorg Med Chem Lett 23(20):5498–5502. https://doi.org/10.1016/j.bmcl.2013.08.071 CrossRefPubMed

Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE (2011) The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J 278(24):4860–4869PubMedPubMedCentral

Miller JR, Edmondson DE (1999a) Influence of flavin analogue structure on the catalytic activities and flavinylation reactions of recombinant human liver monoamine oxidases A and B. J Biol Chem 274(33):23515–23525PubMed

Miller JR, Edmondson DE (1999b) Structure-activity relationships in the oxidation of para- substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 38(41):13670–13683PubMed

Miller HH, Shore PA, Clarke DE (1980) In vivo monoamine oxidase inhibition by d-amphetamine. Biochem Pharmacol 29(10):1347–1354PubMed

Morrison JF (1969) Kinetics of reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269–286. https://doi.org/10.1016/0005-2744(69)90420-3 CrossRefPubMed

Mure M et al (2005) Role of the interactions between the active site base and the substrate Schiff base in amine oxidase catalysis. Evidence from structural and spectroscopic studies of the 2-hydrazinopyridine adduct of Escherichia coli amine oxidase. Biochemistry 44(5):1568–1582. https://doi.org/10.1021/bi047988k CrossRefPubMed

Murphy DL, Donnelly CH, Richelson E, Fuller RW (1978) N-Substituted cyclopropylamines as inhibitors of MAO-A and MAO-B forms. Biochem Pharmacol 27(13):1767–1769PubMed

Murphy DL, Sunderland T, Garrick NA, Aulakh CS, Cohen RM (1987) Selective amine oxidase inhibitors: basic to clinical studies and back. In: Dahl ML, Gram LF, Potter LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin, pp 135–146

Nagy J, Kenney WC, Singer TP (1979) Reaction of phenylhydrazine with trimethylamine dehydrogenase and with free flavins. J Biol Chem 254(8):2684–2688PubMed

Nakai S, Yoneda F, Yamabe T, Fukui K (1999) Inhibition mechanism of flavin by deprenyl as an acetylenic irreversible inhibitor. Theor Chem Acc 102(1–6):147–160

Nandigama RK, Edmondson DE (2000) Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 39(49):15258–15265PubMed

Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y (2011) Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. In: Monoamine oxidases and their inhibitors. Int Rev Neurobiol 100:85–106

Naoi M, Riederer P, Maruyama W (2016) Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm 123(2):91–106. https://doi.org/10.1007/s00702-014-1362-4 CrossRefPubMed

Newton-Vinson P, Hubalek F, Edmondson DE (2000) High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif 20(2):334–345PubMed

Nikolic K, Mavridis L, Djikic T, Vucicevic J, Agbaba D, Yelekci K, Mitchell JBO (2016) Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies. Front Neurosci. https://doi.org/10.3389/fnins.2016.00265 CrossRefPubMedPubMedCentral

Niwa H, Umehara T (2017) Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases. Epigenetics 12(5):340–352. https://doi.org/10.1080/15592294.2017.1290032 CrossRefPubMedPubMedCentral

Oanca G, Purg M, Mavri J, Shih JC, Stare J (2016) Insights into enzyme point mutation effect by molecular simulation: phenylethylamine oxidation catalyzed by monoamine oxidase A. Phys Chem Chem Phys 18(19):13346–13356. https://doi.org/10.1039/c6cp00098c CrossRefPubMed

Orru R, Aldeco M, Edmondson DE (2013) Do MAO A and MAO B utilize the same mechanism for the C–H bond cleavage step in catalysis? Evidence suggesting differing mechanisms. J Neural Transm 120(6):847–851. https://doi.org/10.1007/s00702-013-0991-3 CrossRefPubMedPubMedCentral

Paech C, Salach JI, Singer TP (1980) Suicide inactivation of monoamine-oxidase by trans-phenylcyclopropylamine. J Biol Chem 255(7):2700–2704PubMed

Parent MB, Master S, Kashlub S, Baker GB (2002) Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol 63(1):57–64. https://doi.org/10.1016/S0006-2952(00)00244-6 CrossRefPubMed

Patek DR, Hellerman L (1974) Mitochondrial monoamine-oxidase—mechanism of inhibition by phenylhydrazine and by aralkylhydrazines—role of enzymatic oxidation. J Biol Chem 249(8):2373–2380PubMed

Pavlin M, Mavri J, Repic M, Vianello R (2013) Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. J Neural Transm 120(6):875–882. https://doi.org/10.1007/s00702-013-1016-y CrossRefPubMed

Pearce LB, Roth JA (1985) Human-brain monoamine-oxidase type-B—mechanism of deamination as probed by steady-state methods. Biochemistry 24(8):1821–1826PubMed

Peng L, Zhang G, Zhang D, Wang Y, Zhu D (2010) A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole. Analyst 135(7):1779–1784PubMed

Petzer A, Harvey BH, Wegener G, Petzer JP (2012) Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol App Pharmacol 258(3):403–409

Pisani L, Catto M, Leonetti F, Nicolotti O, Stefanachi A, Campagna F, Carotti A (2011) Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr Med Chem 18(30):4568–4587PubMed

Pisani L et al (2013) Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors. Eur J Med Chem 70:723–739. https://doi.org/10.1016/j.ejmech.2013.09.034 CrossRefPubMed

Prusevich P et al (2014) A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol 9(6):1284–1293. https://doi.org/10.1021/cb500018s CrossRefPubMedPubMedCentral

Qin XZ, Williams F (1987) ESR studies on the radical cation mechanism of the ring opening of cyclopropylamines. J Am Chem Soc 109(2):595–597. https://doi.org/10.1021/ja00236a055 CrossRef

Ramadan ZB, Wrang ML, Tipton KF (2007) Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. Neurochem Res 32(10):1783–1790. https://doi.org/10.1007/s11064-007-9309-x CrossRefPubMed

Ramsay RR (1991) Kinetic mechanism of monoamine oxidase-A. Biochemistry 30(18):4624–4629PubMed

Ramsay RR (1998) Substrate regulation of monoamine oxidases. J Neural Transm-Suppl 52:139-147PubMed

Ramsay RR, Hunter DJB (2002) Inhibitors alter the spectrum and redox properties of monoamine oxidase A. BBA Proteins Proteom 1601(2):178–184

Ramsay RR, Tipton KF (2017) Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules22071192 CrossRef

Ramsay RR, Koerber SC, Singer TP (1987) Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase-B. Biochemistry 26(11):3045–3050PubMed

Ramsay RR, Sablin SO, Singer TP (1995) Redox properties of the flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism. Prog Brain Res 106:33–39PubMed

Ramsay RR, Upadhyay AK, Li M, Edmondson DE (eds) (2005) Optical and EPR spectroscopic studies on the anionic flavin radical in MAO B and its Y435 mutant forms. Flavins and flavoproteins 2005. ArchiTect Inc., Tokyo

Ramsay RR, Dunford C, Gillman PK (2007) Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 152(6):946–951PubMedPubMedCentral

Ramsay RR, Olivieri A, Holt A (2011) An improved approach to steady-state analysis of monoamine oxidases. J Neural Transm 118(7):1003–1019PubMed

Rebrin I, Geha RM, Chen K, Shih JC (2001) Effects of carboxyl-terminal truncations on the activity and solubility of human monoamine oxidase B. J Biol Chem 276(31):29499–29506PubMed

Reck F, Zhou F, Girardot M, Kern G, Eyermann CJ, Hales NJ, Ramsay RR, Gravestock MB (2005) Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 48(2):499–506PubMed

Reynolds GP, Rausch WD, Riederer P (1980) Effects of tranylcypromine stereoisomers on monamine oxidation in man. Br J Clin Pharmacol 9(5):521–523PubMedPubMedCentral

Riederer P, Jellinger K (1983) Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta Neurol Scand Suppl 95:43–55PubMed

Rigby SEJ, Hynson RMG, Ramsay RR, Munro AW, Scrutton NS (2005) A stable tyrosyl radical in monoamine oxidase A. J Biol Chem 280(6):4627–4631PubMed

Rusjan PM, Wilson AA, Miler L, Fan I, Mizrahi R, Houle S, Vasdev N, Meyer JH (2014) Kinetic modeling of the monoamine oxidase B radioligand [(1)(1)C]SL25.1188 in human brain with high-resolution positron emission tomography. J Cereb Blood Flow Metab 34(5):883–889. https://doi.org/10.1038/jcbfm.2014.34 CrossRefPubMedPubMedCentral

Sablin SO, Ramsay RR (2001) Substrates but not inhibitors alter the redox potentials of monoamine oxidases. Antioxid Redox Signal 3(5):723–729PubMed

Salsali M, Holt A, Baker GB (2004) Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 24(1):63–76PubMed

Santillo MF (2014) Inhibition of monoamine oxidase (MAO) by alpha-ethylphenethylamine and N,alpha-diethylphenethylamine, two compounds related to dietary supplements. Food Chem Toxicol 74:265–269. https://doi.org/10.1016/j.fct.2014.10.009 CrossRefPubMed

Sara W, Valette H, Peyronneau M-A, Bramoullé Y, Coulon C, Curet O, George P, Dollé F, Bottlaender M (2010) [11C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse 64(1):61–69. https://doi.org/10.1002/syn.20703 CrossRef

Schmidt DMZ, McCafferty DG (2007) trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46(14):4408–4416PubMed

Shepard EM, Heggem H, Juda GA, Dooley DM (2003) Inhibition of six copper-containing amine oxidases by the antidepressant drug tranylcypromine. BBA Proteins Proteom 1647(1–2):252–259

Silverman RB (1983) Mechanism of inactivation of monoamine-oxidase by trans-2-phenylcyclopropylamine and the structure of the enzyme-inactivator adduct. J Biol Chem 258(24):14766–14769PubMed

Silverman RB (1995a) Mechanism-based enzyme inactivators. Enzyme Kinet Mech 249:240–283

Silverman RB (1995b) Mechanism-based enzyme inactivators. In: Enzyme kinetics and mechanism, Pt D. Methods Enzymol 249:240–283

Silverman RB (1995c) Radical ideas about monoamine-oxidase. Acc Chem Res 28(8):335–342. https://doi.org/10.1021/ar00056a003 CrossRef

Silverman RB, Hiebert CK (1988) Inactivation of monoamine oxidase-A by the monoamine oxidase-B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine. Biochemistry 27(22):8448–8453PubMed

Silverman RB, Hoffman SJ (1981) N-(1-Methyl)cyclopropylbenzylamine—a novel inactivator of mitochondrial monoamine-oxidase. Biochem Biophys Res Commun 101(4):1396–1401PubMed

Silverman RB, Yamasaki RB (1984) Mechanism-based inactivation of mitochondrial monoamine-oxidase by N-(1-methylcyclopropyl)benzylamine. Biochemistry 23(6):1322–1332. https://doi.org/10.1021/bi00301a046 CrossRefPubMed

Silverman RB, Zieske PA (1985) Mechanism of inactivation of monoamine-oxidase by 1-phenylcyclopropylamine. Biochemistry 24(9):2128–2138PubMed

Silverman RB, Zieske PA (1986) Identification of the amino-acid bound to the labile adduct formed during inactivation of monoamine-oxidase by 1-phenylcyclopropylamine. Biochem Biophys Res Commun 135(1):154–159PubMed

Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr (2014) Computational methods in drug discovery. Pharmacol Rev 66(1):334–395. https://doi.org/10.1124/pr.112.007336 CrossRefPubMedPubMedCentral

Son SY, Ma A, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T (2008) Structure of human monoamine oxidase A at 2.2-angstrom resolution: The control of opening the entry for substrates/inhibitors. PNAS USA 105(15):5739–5744PubMedPubMedCentral

Sterling J et al (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease. J Med Chem 45(24):5260–5279. https://doi.org/10.1021/jm020120c CrossRefPubMed

Swett LR, Martin WB, Taylor JD, Everett GM, Wykes AA, Gladish YC (1963) Structure-activity relations in the pargyline series. Ann N Y Acad Sci 107:891–898PubMed

Szewczuk LM, Culhane JC, Yang M, Majumdar A, Yu H, Cole PA (2007) Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 46(23):6892–6902PubMed

Talele TT (2016) The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules. J Med Chem 59(19):8712–8756. https://doi.org/10.1021/acs.jmedchem.6b00472 CrossRefPubMed

Tan AK, Ramsay RR (1993) Substrate-specific enhancement of the oxidative half-reaction of monoamine-oxidase. Biochemistry 32(9):2137–2143PubMed

Taylor JD, Wykes AA, Gladish YC, Martin WB (1960) New inhibitor of monoamine oxidase. Nature 187:941–942. https://doi.org/10.1038/187941a0 CrossRefPubMed

Tipton KF (1971) Reaction of monoamine oxidase with phenethylhydrazine. Biochem J 121(3):P33

Tipton KF, Spires IPC (1971) Kinetics of phenethylhydrazine oxidation by monoamine oxidase. Biochem J 125(2):521–524. https://doi.org/10.1042/bj1250521 CrossRefPubMedPubMedCentral

Tipton KF, Davey G, Motherway M (2006) Monoamine oxidase assays. In: Current protocols in toxicology 30:4.21:4.21.1–4.21.42

Tsugeno Y, Ito A (1997) A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. J Biol Chem 272(22):14033–14036. https://doi.org/10.1074/jbc.272.22.14033 CrossRefPubMed

Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M (2017) Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem 127:470–492. https://doi.org/10.1016/j.ejmech.2017.01.011 CrossRefPubMed

Umhau S, Pollegioni L, Molla G, Diederichs K, Welte W, Pilone M, Ghisla S (2000) The X-ray structure of d-amino acid oxidase at very high resolution identifies the chemical mechanism of flavin-dependent substrate dehydrogenation. PNAS USA 97(23):12463–12468. https://doi.org/10.1073/pnas.97.23.12463 CrossRefPubMedPubMedCentral

Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MBH, Tipton KF, Marco-Contelles J (2016) Multi-target directed donepezil-like ligands for Alzheimer’s disease. Front Neurosci. https://doi.org/10.3389/fnins.2016.00205 CrossRefPubMedPubMedCentral

Upadhyay AK, Borbat PP, Wang J, Freed JH, Edmondson DE (2008) Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-d-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy. Biochemistry 47(6):1554–1566PubMed

Valley MP et al (2006) A bioluminescent assay for monoamine oxidase activity. Anal Biochem 359(2):238–246. https://doi.org/10.1016/j.ab.2006.09.035 CrossRefPubMed

Vazquez ML, Silverman RB (1985) Revised mechanism for inactivation of mitochondrial monoamine-oxidase by N-cyclopropylbenzylamine. Biochemistry 24(23):6538–6543PubMed

Veselovsky AV, Ivanov AS, Medvedev AE (2004) Computer modelling and visualization of active site of monoamine oxidases. Neurotoxicology 25(1–2):37–46PubMed

Vianello R, Repic M, Mavri J (2012) How are biogenic amines metabolized by monoamine oxidases? Eur J Org Chem 36:7057–7065

Vianello P et al (2014) Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. Eur J Med Chem 86:352–363. https://doi.org/10.1016/j.ejmech.2014.08.068 CrossRefPubMed

Vianello R, Domene C, Mavri J (2016) The use of multiscale molecular simulations in understanding a relationship between the structure and function of biological systems of the brain: the application to monoamine oxidase enzymes. Front Neurosci. https://doi.org/10.3389/fnins.2016.00327 CrossRefPubMedPubMedCentral

Vintem APB, Price NT, Silverman RB, Ramsay RR (2005) Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorg Med Chem 13(10):3487–3495PubMed

Walker MC, Edmondson DE (1994) Structure-activity-relationships in the oxidation of benzylamine analogs by bovine liver mitochondrial monoamine-oxidase-B. Biochemistry 33(23):7088–7098PubMed

Wang J, Edmondson DE (2011) H-2 kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme. Biochemistry 50(35):7710–7717. https://doi.org/10.1021/bi200951z CrossRefPubMed

Weinreb O, Amit T, Bar-Am O, Youdim MBH (2010) Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 92(3):330–344PubMed

Weinreb O, Amit T, Riederer P, Youdim MBH, Mandel SA (2011) Neuroprotective profile of the multitarget drug rasagiline in Parkinson’s disease. In: Youdim MBH (ed) Monoamine oxidases and their inhibitors. Int Rev Neurobiol 100:127–149

Werther T, Wahlefeld S, Salewski J, Kuhlmann U, Zebger I, Hildebrandt P, Dobbek H (2017) Redox-dependent substrate-cofactor interactions in the Michaelis-complex of a flavin-dependent oxidoreductase. Nat Commun 8:16084. https://doi.org/10.1038/ncomms16084 CrossRefPubMedCentral

Weyler W (1994) Functional expression of C-terminally truncated human monoamine-oxidase type-a in Saccharomyces cerevisiae. J Neural Transm Suppl 41:3–15PubMed

Williams CH, Lawson J (1974) Monoamine oxidase. II. Time-dependent inhibition by propargylamines. Biochem Pharmacol 23(3):629–636PubMed

Wu HF, Chen K, Shih JC (1993) Site-directed mutagenesis of monoamine oxidase-A and oxidase-B—role of cysteines. Mol Pharmacol 43(6):888–893PubMed

Wu XF, Li LH, Shi W, Gong QY, Li XH, Ma HM (2016) Sensitive and selective ratiometric fluorescence probes for detection of intracellular endogenous monoamine oxidase A. Anal Chem 88(2):1440–1446. https://doi.org/10.1021/acs.analchem.5b04303 CrossRefPubMed

Xie SS, Wang XB, Jiang N, Yu WY, Wang KDG, Lan JS, Li ZR, Kong LY (2015) Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer’s disease. Eur J Med Chem 95:153–165. https://doi.org/10.1016/j.ejmech.2015.03.040 CrossRefPubMed

Yang HY, Neff NH (1974) The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189(3):733–740PubMed

Youdim MBH, Tipton KF (2002) Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson’s disease. Parkinsonism Relat Disord 8(4):247–253. https://doi.org/10.1016/s1353-8020(01)00011-6 CrossRefPubMed

Youdim MB, Collins GG, Sandler M (1971) Monoamine oxidase: multiple forms and selective inhibitors. Biochem J 121:32P–34P

Youdim MBH, Wadia A, Tatton W, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. In: Slikker W, Trembly B (eds) Neuroprotective agents. Ann N Y Acad Sci, vol 939, pp 450–458

Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309PubMed

Youngster SK, McKeown KA, Jin YZ, Ramsay RR, Heikkila RE, Singer TP (1989) Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase-A and oxidase-B and the inhibition of monoamine oxidases by the oxidation products. J Neurochem 53(6):1837–1842PubMed

Yu PH (1994) Pharmacological and clinical implications of MAO-B inhibitors. Gen Pharmacol 25(8):1527–1539PubMed

Yu PH, Tipton KF (1989) Deuterium-isotope effect of phenelzine on the inhibition of rat-liver mitochondrial monoamine-oxidase activity. Biochem Pharmacol 38(23):4245–4251PubMed

Yu PH, Bailey BA, Durden DA, Boulton AA (1986) Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAOA and MAOB from different tissues. Biochem Pharmacol 35(6):1027–1036PubMed

Zeller EA, Barsky J (1952) In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc Soc Exper Bio Med 81(2):459–461

Zeller EA, Sarkar S (1962) Amine oxidases. XIX. Inhibition of monoamine oxidase by phenylcyclopropylamines and iproniazid. J Biol Chem 237:2333–2336PubMed

Zenn RK, Abad E, Kastner J (2015) Influence of the environment on the oxidative deamination of p-substituted benzylamines in monoamine oxidase. J Phys Chem B 119(9):3678–3686. https://doi.org/10.1021/jp512470a CrossRefPubMed

Zhong BY, Silverman RB (1997) Identification of the active site cysteine in bovine liver monoamine oxidase B. J Am Chem Soc 119(28):6690–6691

Titel: Kinetics, mechanism, and inhibition of monoamine oxidase
verfasst von: Rona R. Ramsay
Alen Albreht
Publikationsdatum: 07.03.2018
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 11/2018
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-018-1861-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons

The structure of monoamine oxidases: past, present, and future

Monoamine oxidase-A, serotonin and norepinephrine: synergistic players in cardiac physiology and pathology

Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects

Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy